NOXAFIL Drug Patent Profile

Which patents cover Noxafil, and when can generic versions of Noxafil launch?

Noxafil is a drug marketed by Merck Sharp Dohme, Schering, and Msd Merck Co. and is included in four NDAs. There are six patents protecting this drug and three Paragraph IV challenges.

This drug has eighty-one patent family members in twenty-four countries.

The generic ingredient in NOXAFIL is posaconazole. There are twenty-one drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the posaconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Noxafil

A generic version of NOXAFIL was approved as posaconazole by SINOTHERAPEUTICS INC on August 21^st, 2019.

Summary for NOXAFIL

International Patents:	81
US Patents:	6
Applicants:	3
NDAs:	4
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	24
Patent Applications:	2,088
Drug Prices:	Drug price information for NOXAFIL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOXAFIL
What excipients (inactive ingredients) are in NOXAFIL?	NOXAFIL excipients list
DailyMed Link:	NOXAFIL at DailyMed

See drug prices for NOXAFIL

Recent Clinical Trials for NOXAFIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Milton S. Hershey Medical Center	Early Phase 1
M.D. Anderson Cancer Center	Phase 1/Phase 2
Cidara Therapeutics Inc.	Phase 3

See all NOXAFIL clinical trials

Pharmacology for NOXAFIL

Drug Class

Azole Antifungal

Paragraph IV (Patent) Challenges for NOXAFIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NOXAFIL	Injection	posaconazole	18 mg/mL, 16.7 mL vials	205596	1	2015-11-24
NOXAFIL	Delayed-release Tablets	posaconazole	100 mg	205053	1	2014-06-16
NOXAFIL	Oral Suspension	posaconazole	40 mg/mL	022003	1	2011-02-28

US Patents and Regulatory Information for NOXAFIL

NOXAFIL is protected by thirteen US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No			Y
Merck Sharp Dohme	NOXAFIL	posaconazole	TABLET, DELAYED RELEASE;ORAL	205053-001	Nov 25, 2013		DISCN	Yes	No
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No			Y
Msd Merck Co	NOXAFIL POWDERMIX KIT	posaconazole	FOR SUSPENSION, DELAYED RELEASE;ORAL	214770-001	May 31, 2021		RX	Yes	Yes
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	AB	RX	Yes	Yes

Expired US Patents for NOXAFIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006

EU/EMA Drug Approvals for NOXAFIL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Noxafil	posaconazole	EMEA/H/C/000610Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.	Authorised	no	no	no	2005-10-25
Accord Healthcare S.L.U.	Posaconazole AHCL	posaconazole	EMEA/H/C/005028Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Authorised	yes	no	no	2019-07-25
Accord Healthcare S.L.U.	Posaconazole Accord	posaconazole	EMEA/H/C/005005Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients: Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Authorised	yes	no	no	2019-07-25
Schering-Plough Europe	Posaconazole SP	posaconazole	EMEA/H/C/000611Posaconazole SP is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole SP is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Withdrawn	no	no	no	2005-10-25

International Patents for NOXAFIL

See the table below for patents covering NOXAFIL around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	002751	ANTIFUNGICOS DE TETRAHIDROFURANO, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y EL USO DE LOS COMPUESTOS PARA PREPARAR COMPOSICIONES FARMACEUTICAS UTILES PARA EL TRATAMIENTO DE INFECCIONES FUNGICAS
Austria	204875
Austria	240319
Australia	1512795
Australia	5928096

Supplementary Protection Certificates for NOXAFIL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0736030	91216	Luxembourg		91216, EXPIRES: 20191220
0736030	CA 2006 00002	Denmark
0736030	300219	Netherlands		300219, 20141220, EXPIRES: 20191219
0736030	SPC003/2006	Ireland		SPC003/2006: 20061023, EXPIRES: 20191219
0736030	06C0009	France		PRODUCT NAME: POSACONAZOLE; REGISTRATION NO/DATE: EU/1/05/320/001 20051025

Noxafil (Posaconazole) Market Dynamics and Financial Trajectory (Revenue, Exclusivity, and Competitive Pressure)

Last updated: July 24, 2026

Noxafil (posaconazole) has two major commercial drivers: expanded clinician adoption in invasive fungal disease (IFD) and loss of exclusivity and competitive erosion from lower-cost azole generics. Financial trajectory is shaped less by near-term patent cliffs (posaconazole has extensive generic headwinds) and more by channel pricing, payer formulary status, and how quickly competing products displace Noxafil across prophylaxis and treatment settings.

---

How has Noxafil (posaconazole) revenue trended since launch?

Answer: Noxafil has historically generated meaningful oncology and transplant-related revenue, but the long-term trajectory is pressured by generic posaconazole entry in oral formulations, channel contracting, and broader azole competition (voriconazole, isavuconazole). Net sales growth is typically replaced by revenue stabilization then decline in the most exposed dose forms.

Revenue exposure by segment and use case

• Oncology prophylaxis (neutropenia/chemotherapy regimens): tends to remain more resilient when formularies treat posaconazole as preferred, but is sensitive to tendering in large hospital systems.
• Transplant and graft-versus-host disease (GVHD) prophylaxis: often uses posaconazole when breakthrough infection risk is judged high; adoption can persist even after generic substitution if hospital protocols lag switching.
• Treatment of breakthrough IFD: higher unit intensity, but payer step-edits and “preferred alternatives” drive switches when generics are available.

Key financial dynamics that move margins

• WAC-to-net compression: Noxafil’s economics depend on discounts, rebates, and access fees in hematology/oncology accounts.
• Formulation mix: Different Noxafil oral suspensions vs later oral solid approaches have different switching dynamics to generics.
• Hospital tender cycles: Large group purchasing can rapidly shift volume after generic availability.

---

What drives Noxafil market demand in invasive fungal disease and prophylaxis?

Answer: Clinical need is stable in IFD risk populations. The demand curve is influenced by (1) antifungal guideline positioning, (2) prophylaxis protocols in oncology and transplant care, and (3) changes in disease epidemiology (breakthrough breakthrough rates, resistant species mix).

Primary clinical demand centers

• Acute myeloid leukemia (AML) and high-risk neutropenia prophylaxis
• Hematopoietic stem cell transplant (HSCT) prophylaxis
• GVHD prophylaxis
• Refractory or breakthrough invasive aspergillosis and other IFDs

Competitive clinical substitution pressure

• Isavuconazole and voriconazole compete in prophylaxis and treatment pathways where local guidelines allow interchange.
• Echinocandin co-therapy may reduce azole monotherapy share in some stewardship protocols, though posaconazole retains a role for specific indications.

---

Which generic and brand competitors most pressure Noxafil pricing and volume?

Answer: The dominant economic pressure comes from lower-cost posaconazole generics after entry, plus alternative antifungals that can satisfy prophylaxis and treatment criteria.

Typical competitive set in IFD formularies

• Generic posaconazole oral products (major direct displacement)
• Isavuconazole (brand market share defense through clinician preference in some geographies)
• Voriconazole (older azole with broader generic availability but differing safety and monitoring burden)
• Echinocandins (treatment options that can shift use patterns in certain settings)

What matters for conversion from Noxafil

• Therapeutic drug monitoring (TDM) requirements that increase workflow friction for alternatives
• Dosing convenience and absorption profile for oral prophylaxis
• Payer coverage rules that favor the lowest net-cost “preferred antifungal”

---

When does Noxafil lose exclusivity for key formulations, and what does that imply for revenue?

Answer: Noxafil’s long-term financial path is best explained by generic erosion rather than a single “cliff.” Posaconazole exclusivity has been segmented across formulation types and patent families, leading to stepwise volume loss.

Exclusivity and patent estate structure that drives revenue timing

• Composition-of-matter and formulation patents historically support brand pricing.
• Additional formulation and method-use patents can delay generic entry in some dosage forms, but generic substitution still typically accelerates after the strongest barriers fall.
• Paragraph IV and settlement cycles (when they occurred for posaconazole-related filings) typically map to step-changes in unit volume and pricing rather than gradual decline.

Practical revenue implication

• Revenue tends to plateau after the first material generic entry, then declines faster when formulary switches and tendering propagate across oncology and transplant institutions.
• The brand often retains share in accounts with:
  • established protocol adherence,
  • clinician familiarity,
  • supply continuity requirements.

---

What Orange Book status governs generic entry risk for Noxafil?

Answer: Noxafil’s generic entry risk is governed by Orange Book-listed patents covering the marketed posaconazole product(s), with different risk windows by dosage form and strength.

How Orange Book listings translate into market impact

• Patents that block generic approval trigger slower generic uptake.
• When generics obtain approval, real-world displacement depends on:
  • payer preferred status,
  • hospital switching incentives,
  • contracting timelines.

Market mechanism after approval

• Even after FDA approval, procurement cycles can take months to fully reflect new pricing.

---

What patent litigation and Paragraph IV challenges shaped Noxafil’s market timeline?

Answer: Posaconazole market history has included generic challenges and litigation affecting entry timing for specific oral formulations and strengths. Those events typically align with stepwise reductions in brand share.

Litigation-to-commercial mapping

• ANDA filings alleging invalidity or non-infringement (often Paragraph IV) can:
  • delay initial FDA approval entry,
  • lead to settlements that shift the “first commercial” date window,
  • shape which generic manufacturers enter first (impacting price competition intensity).

---

How do Noxafil formulation differences affect substitution and financial trajectory?

Answer: Formulation has been central to Noxafil’s economics because absorption and dosing consistency influence prescriber preference and payer acceptability.

Oral suspension vs oral solid dynamics

• Suspension absorption variability historically required careful attention in prophylaxis settings, which can increase clinician comfort with branded regimens if protocols are stable.
• Oral solid development (where applicable in the commercial product line) can improve ease of administration and TDM strategy, impacting switching speed.

Switching velocity by setting

• In standardized prophylaxis pathways, switching is faster once pharmacy committees adopt generics.
• In complex treatment settings (breakthrough IFD), switching can lag due to clinical caution.

---

What regulatory milestones and FDA pathway issues matter for Noxafil’s market performance?

Answer: For Noxafil, market performance is less about new FDA milestones in the near term and more about the regulatory environment that enables generic substitution and competitor approvals.

Competitive regulatory effects

• Generic approvals drive pricing pressure.
• Competitor label expansions can re-route prophylaxis and treatment selection away from posaconazole.

---

How does Noxafil compare with isavuconazole and voriconazole on market access economics?

Answer: Noxafil competes on clinical performance in high-risk prophylaxis and some IFD treatment pathways, but pricing access depends on generic availability and payer contracts. Isavuconazole tends to compete on ease of use and dosing profile. Voriconazole often faces monitoring burden economics, but can be discounted aggressively due to generic availability.

Typical payer decision logic

• If posaconazole is “preferred,” coverage is maintained for high-risk indications.
• If generic posaconazole is available at materially lower net cost, payer incentives can override brand differentiation.
• Step therapy is common when alternatives are clinically acceptable.

---

Which companies are best positioned to capture share after Noxafil generic entry?

Answer: Share tends to consolidate toward manufacturers with:

• rapid supply scaling,
• strong contracting with large wholesalers and group purchasing organizations,
• product availability across dosage forms used in formularies.

How distribution strength influences outcomes

• Fast tender adoption beats slower clinical conversion.
• Wholesaler rebates and payer contracting can determine who wins hospital volume post-entry.

---

How many patents cover Noxafil, and how strong is the remaining estate?

Answer: Posaconazole’s broader patent landscape is typically dense, spanning composition-of-matter, formulation, and potentially method-of-use. For the branded market, the practical consequence is that generic displacement windows were spread over time, not concentrated into a single termination.

Patent strength in commercial terms

• Stronger estates usually delay early entry, but broad downstream generic availability still limits long-horizon brand revenue.
• Any remaining protection generally translates to:
  • reduced speed of erosion for a specific dosage form,
  • narrower pricing leverage for the brand.

---

What generic entry risks exist for Noxafil across geographies?

Answer: Erosion risk is structurally high across major markets once sufficient freedom-to-operate emerges and generics obtain approvals. The pace varies with:

• local patent enforcement,
• litigation outcomes,
• health technology assessment (HTA) and reimbursement rules.

Cross-market behavior

• EU and UK: HTA and tendering can accelerate volume shift once generics are available.
• US: FDA approval is necessary but not sufficient; payer and contracting determine uptake.

---

How do settlement agreements affect real-world Noxafil pricing and volume?

Answer: Settlements that enable earlier generic entry or clarify product scope typically lead to:

• reduced brand purchasing over time,
• faster payer substitution if the generic’s net cost is favorable,
• competitive price resets in hospitals.

Settlement impact is most visible in

• wholesale acquisition price revisions,
• rebate renegotiations,
• formulary tier changes in hematology and oncology.

---

Key timeline: what commercialization events typically define Noxafil’s financial trajectory?

Answer: Noxafil’s financial path is defined by generic entry milestones rather than new clinical breakthroughs.

Market timeline pattern (stepwise)

• Brand stabilization period: premium pricing with restricted competition.
• First significant generic entry: plateau to mild decline.
• Wider generic availability plus contracting: accelerated decline.
• Long-term equilibrium: low single-digit or mid-single-digit erosion rate depending on tender consolidation and alternative antifungal adoption.

(Specific dates are product- and formulation-dependent and vary by strength and jurisdiction.)

---

Revenue sensitivity: what drives quarter-to-quarter Noxafil financial swings?

Answer: The biggest drivers are:

• uptake of generics in pharmacy and therapeutics committees,
• reimbursement and formulary changes,
• pricing concessions and wholesaler channel inventory dynamics.

What to track for financial forecasting

• hospital purchasing share by antifungal class,
• net pricing trend versus WAC,
• competitor share movements (isavuconazole, voriconazole),
• stocking behavior around generic releases.

---

Key Takeaways

• Noxafil’s long-term financial trajectory is primarily constrained by generic posaconazole displacement and payer formulary dynamics rather than ongoing brand exclusivity.
• Market demand in IFD remains stable, but brand revenue is vulnerable to net price erosion once generics become preferred.
• Formulation and absorption-related clinical protocols can delay switching in some treatment settings, but contracting usually dominates in high-volume prophylaxis pathways.
• Competitive pressure comes from both generic posaconazole and alternative antifungals, with payer economics determining final selection.

---

FAQs

1) Does Noxafil still hold formulary preference after posaconazole generics enter?

Often partially. Preference can persist in high-risk clinical protocols, but net-cost contracting and tendering frequently push conversion to generics.

2) Which Noxafil indications are most resistant to generic substitution?

Breakthrough or refractory IFD treatment pathways can switch later than standardized prophylaxis, but timing varies by hospital stewardship and patient mix.

3) How does hospital tendering typically affect Noxafil unit volume?

Tendering can cause abrupt volume shifts when a low-cost supplier becomes the default, often leading to faster share loss than clinical switching alone would predict.

4) What antifungal class shifts most commonly reduce Noxafil share?

Azole substitution by isavuconazole and voriconazole (where coverage allows), plus selective use of echinocandins in treatment algorithms.

5) How should financial models incorporate patent and generic entry timing for Noxafil?

Model stepwise revenue declines aligned to dosage-form specific generic launch and subsequent formulary uptake, rather than a single end-of-exclusivity date.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book database).
2. FDA. Drug Approval Packages and related labeling information for posaconazole (Noxafil). (FDA product pages).
3. EMA. European Medicines Agency assessment history and EPAR documents for posaconazole products. (EMA website).
4. ASM. Antifungal guideline publications (IDSA/ESCMID or local equivalents) covering posaconazole indications and treatment positioning. (Guideline texts).

DrugChatter Q&A for NOXAFIL

Why is noxafil so expensive?
What year was noxafil gastroresistant tablets approved by fda?
Does medicare cover noxafil?